{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:24:37Z","timestamp":1773296677582,"version":"3.50.1"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2008,9,16]],"date-time":"2008-09-16T00:00:00Z","timestamp":1221523200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1007\/s00213-008-1308-3","type":"journal-article","created":{"date-parts":[[2008,9,15]],"date-time":"2008-09-15T04:31:47Z","timestamp":1221453107000},"page":"279-294","source":"Crossref","is-referenced-by-count":21,"title":["Discriminative stimulus properties of atypical and typical antipsychotic drugs: a review of preclinical studies"],"prefix":"10.1007","volume":"203","author":[{"given":"Joseph H.","family":"Porter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam J.","family":"Prus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,9,16]]},"reference":[{"key":"1308_CR1","unstructured":"Arnt J \u03b11-adrenoceptor antagonists substitute for the discriminative stimulus properties of NMDA in rats. Poster presented at the meeting of the Society for Neuroscience, New Orleans, October 1997"},{"key":"1308_CR2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0893-133X(97)00112-7","volume":"18","author":"J Arnt","year":"1998","unstructured":"Arnt J, Skarsfeldt T (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18:63\u2013101","journal-title":"Neuropsychopharmacology"},{"key":"1308_CR3","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/BF00422558","volume":"34","author":"H Barry III","year":"1974","unstructured":"Barry H III, Steenberg ML, Manian AA, Buckley JP (1974) Effects of chlorpromazine and three metabolites on behavioral responses in rats. Psychopharmacology (Berlin) 34:351\u2013360","journal-title":"Psychopharmacology (Berlin)"},{"key":"1308_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0006-8993(94)90002-7","volume":"643","author":"JD Brioni","year":"1994","unstructured":"Brioni JD, Kim DJB, O\u2019Neill AB, Williams JEG, Decker MW (1994) Clozapine attenuates the discriminative stimulus properties of (-)-nicotine. Brain Res 643:1\u20139","journal-title":"Brain Res"},{"key":"1308_CR5","first-page":"241","volume-title":"Drug discrimination: applications in CNS pharmacology","author":"RG Browne","year":"1982","unstructured":"Browne RG, Koe BK (1982) Clozapine and agents with similar behavioral and biochemical properties. In: Colpaert FC, Slangen JL (eds) Drug discrimination: applications in CNS pharmacology. Elsevier Biomedical, Amsterdam, pp 241\u2013254"},{"key":"1308_CR6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","volume":"14","author":"FP Bymaster","year":"1996","unstructured":"Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87\u201396","journal-title":"Neuropsychopharmacology"},{"key":"1308_CR7","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s002130050344","volume":"132","author":"GJ Carey","year":"1997","unstructured":"Carey GJ, Bergman J (1997) Discriminative-stimulus effects of clozapine in squirrel monkeys: comparison with conventional and novel antipsychotic drugs. Psychopharmacology 132:261\u2013269","journal-title":"Psychopharmacology"},{"key":"1308_CR8","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1007\/BF00442559","volume":"99","author":"E Casey","year":"1989","unstructured":"Casey E (1989) Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 99:S47\u2013S53","journal-title":"Psychopharmacology"},{"key":"1308_CR9","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00004714-198712000-00002","volume":"7","author":"J Claghorn","year":"1987","unstructured":"Claghorn J, Honigfeld G, Abuzzanab FS, Wang R, Steinbook R, Tauson V, Klerman G (1987) The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 7:377\u2013384","journal-title":"J Clin Psychopharmacol"},{"key":"1308_CR10","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0022-3565(24)37047-8","volume":"283","author":"C Cohen","year":"1997","unstructured":"Cohen C, Sanger DJ, Perrault G (1997) Characterization of the discriminative stimulus produced by the dopamine antagonist tiapride. J Pharmacol Exp Ther 283:566\u2013573","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"1308_CR11","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/FBP.0b013e32813c5475","volume":"18","author":"JC Cole","year":"2007","unstructured":"Cole JC, Field M, Sumnall HR, Goudie AJ (2007) Potentiation of olanzapine substitution in rats discriminating clozapine by the D2\/3 agonist quinpirole. Behav Pharmacol 18(3):185\u2013190","journal-title":"Behav Pharmacol"},{"issue":"2","key":"1308_CR12","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0091-3057(99)00047-7","volume":"64","author":"FC Colpaert","year":"1999","unstructured":"Colpaert FC (1999) Drug discrimination in neurobiology. Pharmacol Biochem Behav 64(2):337\u2013345","journal-title":"Pharmacol Biochem Behav"},{"key":"1308_CR13","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF00421388","volume":"46","author":"FC Colpaert","year":"1976","unstructured":"Colpaert FC, Niemegeers CJE, Janssen PAJ (1976) Theoretical and methodological considerations on drug discrimination learning. Psychopharmacologia (Berl.) 46:169\u2013177","journal-title":"Psychopharmacologia (Berl.)"},{"key":"1308_CR14","first-page":"92","volume-title":"The biochemical basis of neuropharmacology","author":"JR Cooper","year":"1996","unstructured":"Cooper JR, Bloom FE, Roth RH (1996) The biochemical basis of neuropharmacology. Oxford University Press, New York, p 92"},{"key":"1308_CR15","first-page":"178","volume-title":"Neurochemistry and neuropharmacology of Schizophrenia","author":"T Crow","year":"1987","unstructured":"Crow T (1987) Positive and negative symptoms in schizophrenia. In: Henn FA, DeLisi LE (eds) Neurochemistry and neuropharmacology of Schizophrenia. Elsevier Science, New York, pp 178\u2013189"},{"key":"1308_CR16","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00213-004-2017-1","volume":"178","author":"MA Davies","year":"2004","unstructured":"Davies MA, Compton-Toth BA, Hufeisen SJ, Meltzer HY, Roth BL (2004) The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M(1) agonism a pre-requisite for mimicking clozapine\u2019s actions? Psychopharmacology 178:451\u2013460","journal-title":"Psychopharmacology"},{"key":"1308_CR17","doi-asserted-by":"crossref","unstructured":"Dekeyne A, Iob L, Millan MJ (2003) Generalization of clozapine as compared to other antipsychotic agents to a discriminative stimulus elicited by the serotonin (5-HT)2A antagonist, MDL100,907. Neuropharmacology 44:604\u2013615","DOI":"10.1016\/S0028-3908(03)00040-6"},{"key":"1308_CR18","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2146\/ajhp070261","volume":"65","author":"C Dolder","year":"2008","unstructured":"Dolder C, Nelson M, Deyo Z (2008) Paliperidone for schizophrenia. Am J Health-Syst Pharm 65:403\u2013413","journal-title":"Am J Health-Syst Pharm"},{"key":"1308_CR19","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1517\/14656566.8.14.2307","volume":"8","author":"H Dlugosz","year":"2007","unstructured":"Dlugosz H, Nasrallah HA (2007) Paliperidone: a new extended-release oral atypical antipsychotic. Expert Opin Pharmacother 8:2307\u20132313","journal-title":"Expert Opin Pharmacother"},{"key":"1308_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0163-7258(93)90036-D","volume":"57","author":"BA Ellenbroek","year":"1993","unstructured":"Ellenbroek BA (1993) Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs. Pharmac Ther 57:1\u201378","journal-title":"Pharmac Ther"},{"key":"1308_CR21","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/00008877-199000160-00001","volume":"1","author":"BA Ellenbroek","year":"1990","unstructured":"Ellenbroek BA, Cools A (1990) Animals models with construct validity for schizophrenia. Behav Pharmacol 1:469\u2013490","journal-title":"Behav Pharmacol"},{"key":"1308_CR22","first-page":"113","volume":"5","author":"SR Franklin","year":"1994","unstructured":"Franklin SR, Tang AH (1994) Discriminative stimulus effects of clozapine in rats. Behav Pharmacol 5:113","journal-title":"Behav Pharmacol"},{"key":"1308_CR23","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1177\/026988119801200111","volume":"12","author":"D Gauvin","year":"1998","unstructured":"Gauvin D, Vanacek SA, Baird TJ, Briscoe RJ, Carl KL, Holloway FA, Sannerud CA (1998) The stimulus properties of two common over-the-counter drug mixtures: dextromethorphan + ephedrine and dextromethorphan + diphenhydramine. J Psychopharmacol 12:84\u201392","journal-title":"J Psychopharmacol"},{"key":"1308_CR24","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.pnpbp.2003.09.003","volume":"27","author":"MA Geyer","year":"2003","unstructured":"Geyer MA, Ellenbroek B (2003) Animal behavior models of the mechanisms underlying antipsychotic atypicality. Progress Neuro-Psychopharmacol & Biol Psychiatry 27:1071\u20131079","journal-title":"Progress Neuro-Psychopharmacol & Biol Psychiatry"},{"issue":"Suppl 10","key":"1308_CR25","first-page":"42","volume":"60","author":"WM Glazer","year":"1999","unstructured":"Glazer WM (1999) Does loxapine have \u201catypical\u201d properties? Clinical evidence. J Clin Psychiatry 60(Suppl 10):42\u201346","journal-title":"J Clin Psychiatry"},{"key":"1308_CR26","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0091-3057(78)90310-6","volume":"8","author":"JA Goas","year":"1978","unstructured":"Goas JA, Boston JE Jr (1978) Discriminative stimulus properties of clozapine and chlorpromazine. Pharmacol Biochem Behav 8:235\u2013241","journal-title":"Pharmacol Biochem Behav"},{"key":"1308_CR27","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1476-5381.1980.tb14570.x","volume":"68","author":"PR Golds","year":"1980","unstructured":"Golds PR, Przyslo FR, Strange PG (1980) The binding of some antidepressant drugs to brain muscarinic acetylcholine receptors. British J Pharmacol 68:541\u2013549","journal-title":"British J Pharmacol"},{"issue":"2","key":"1308_CR28","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0091-3057(99)00079-9","volume":"64","author":"AJ Goudie","year":"1999","unstructured":"Goudie AJ, Smith JA (1999) Discriminative stimulus properties of antipsychotics. Pharmacol Biochem Behav 64(2):193\u2013201","journal-title":"Pharmacol Biochem Behav"},{"key":"1308_CR29","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s002130050527","volume":"135","author":"AJ Goudie","year":"1998","unstructured":"Goudie AJ, Taylor A (1998a) Comparative characterisation of the discriminative stimulus properties of clozapine and other antipsychotics in rats. Psychopharmacology 135:392\u2013400","journal-title":"Psychopharmacology"},{"key":"1308_CR30","first-page":"54","volume":"124S","author":"AJ Goudie","year":"1998","unstructured":"Goudie AJ, Taylor A (1998b) Olanzapine generalisation to the clozapine discriminative stimulus is determined by clozapine training dose. British J Pharmacol 124S:54","journal-title":"British J Pharmacol"},{"issue":"Suppl","key":"1308_CR31","first-page":"226","volume":"12","author":"AJ Goudie","year":"1998","unstructured":"Goudie AJ, Taylor MAI, Smith JA (1998a) Stimulus properties of clozapine and related agents in rats at two clozapine training doses. J Psychopharmacol 12(Suppl):226","journal-title":"J Psychopharmacol"},{"issue":"Suppl","key":"1308_CR32","first-page":"A57","volume":"12","author":"AJ Goudie","year":"1998","unstructured":"Goudie AJ, Taylor MAI, Smith JA (1998b) Converting olanzapine into clozapine in rats. J Psychopharmacol 12(Suppl):A57","journal-title":"J Psychopharmacol"},{"key":"1308_CR33","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/00008877-199812000-00006","volume":"9","author":"AJ Goudie","year":"1998","unstructured":"Goudie AJ, Smith JA, Taylor A, Taylor MAI, Tricklebank MD (1998c) Discriminative stimulus properties of the atypical neuroleptic clozapine in rats: tests with subtype selective receptor ligands. Behav Pharmacol 9:699\u2013710","journal-title":"Behav Pharmacol"},{"key":"1308_CR34","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00008877-200109000-00001","volume":"12","author":"AJ Goudie","year":"2001","unstructured":"Goudie AJ, Baker LE, Smith JA, Prus AJ, Svensson KA, Cortes-Burgos LA, Wong EHF, Haadsma-Svensson S (2001) Common discriminative stimulus properties in rats of muscarinic antagonists, clozapine and the D3 preferring antagonist PNU-99194A: an analysis of possible mechanisms. Behav Pharmacol 12:303\u2013315","journal-title":"Behav Pharmacol"},{"key":"1308_CR35","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.pbb.2003.10.012","volume":"77","author":"AJ Goudie","year":"2004","unstructured":"Goudie AJ, Smith JA, Cole JC (2004a) Stimulus properties of the \u201catypical\u201d antipsychotic zotepine in rats: comparisons with clozapine and quetiapine. Pharmacol Biochem Behav 77:163\u2013173","journal-title":"Pharmacol Biochem Behav"},{"key":"1308_CR36","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s00213-003-1576-x","volume":"171","author":"AJ Goudie","year":"2004","unstructured":"Goudie AJ, Smith JA, Millan MJ (2004b) Characterization of the effects of receptor-selective ligands in rats discriminating the novel antipsychotic quetiapine. Psychopharmacology 171:212\u2013222","journal-title":"Psychopharmacology"},{"issue":"2","key":"1308_CR37","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/0269881107067076","volume":"21","author":"AJ Goudie","year":"2006","unstructured":"Goudie AJ, Cooper GD, Cole JC, Sumnall HR (2006) Cyproheptadine resembles clozapine in vivo following both acute and chronic administration in rats. J Psychopharmacol 21(2):179\u2013190","journal-title":"J Psychopharmacol"},{"key":"1308_CR38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/FBP.0b013e328014138d","volume":"18","author":"AJ Goudie","year":"2007","unstructured":"Goudie AJ, Cole JC, Sumnall HR (2007) Olanzapine and JL13 induce cross-tolerance to the clozapine discriminative stimulus in rats. Behav Pharmacol 18:9\u201317","journal-title":"Behav Pharmacol"},{"key":"1308_CR39","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-1-4757-0788-5_7","volume-title":"Stimulus properties of drugs","author":"RT Harris","year":"1971","unstructured":"Harris RT, Balster RL (1971) An analysis of the function of drugs in the stimulus control of operant behavior. In: Thompson T, Pickens R (eds) Stimulus properties of drugs. Meredith, New York, NY, pp 111\u2013132"},{"key":"1308_CR40","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0022-3565(25)10336-4","volume":"263","author":"EM Hoenicke","year":"1992","unstructured":"Hoenicke EM, Vanecek SA, Woods JH (1992) The discriminative stimulus effects of clozapine in pigeons: involvement of 5-hydroxytryptamine-1c and 5-hydroxytryptamine-2 receptors. J Pharmacol Exp Ther 263:276\u2013284","journal-title":"J Pharmacol Exp Ther"},{"key":"1308_CR41","first-page":"77","volume":"1","author":"G Honigfeld","year":"1984","unstructured":"Honigfeld G, Patin J, Singer J (1984) Clozapine: antipsychotic activity in treatment-resistant schizophrenics. Adv Ther 1:77\u201397","journal-title":"Adv Ther"},{"key":"1308_CR42","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0006-8993(94)91413-3","volume":"647","author":"A Imperato","year":"1994","unstructured":"Imperato A, Dazzi L, Obinu MC, Gessa GL, Biggio G (1994) The benzodiazepine receptor antagonist flumazenil increases acetylcholine release in rat hippocampus. Brain Res 647:167\u2013171","journal-title":"Brain Res"},{"key":"1308_CR43","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/0278-5846(94)90013-2","volume":"18","author":"F Jenck","year":"1994","unstructured":"Jenck F, Moreau J-L, Mutel V, Martin JR (1994) Brain 5-HT1C receptors and antidepressants. Prog Neuropsychopharmacol Psychiatry 18:563\u2013574","journal-title":"Prog Neuropsychopharmacol Psychiatry"},{"key":"1308_CR44","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","volume":"45","author":"J Kane","year":"1988","unstructured":"Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison versus chlorpromazine\/benztropine. Arch Gen Psychiatry 45:789\u2013796","journal-title":"Arch Gen Psychiatry"},{"key":"1308_CR45","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1124\/jpet.102.046987","volume":"305","author":"S Kapur","year":"2003","unstructured":"Kapur S, Vanderspek SC, Brownlee BA, Nobrega JN (2003) Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 305:625\u2013631","journal-title":"J Pharmacol Exp Ther"},{"key":"1308_CR46","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0091-3057(96)00342-5","volume":"57","author":"BM Kelley","year":"1997","unstructured":"Kelley BM, Porter JH (1997) The role of muscarinic cholinergic receptors in the discriminative stimulus properties of clozapine in rats. Pharmacol Biochem Behav 57:707\u2013719","journal-title":"Pharmacol Biochem Behav"},{"key":"1308_CR47","first-page":"1637","volume":"20","author":"BM Kelley","year":"1994","unstructured":"Kelley BM, Nuti KA, Porter JH (1994) Further evidence for muscarinic antagonism as clozapine\u2019s discriminative stimulus. Society for Neuroscience Abstracts 20:1637","journal-title":"Society for Neuroscience Abstracts"},{"key":"1308_CR48","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/BF02245823","volume":"120","author":"BM Kelley","year":"1995","unstructured":"Kelley BM, Porter JH, Varvel SA (1995) Mianserin as a discriminative stimulus in rats: asymmetrical cross-generalization with scopolamine. Psychopharmacology 120:491\u2013493","journal-title":"Psychopharmacology"},{"key":"1308_CR49","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1192\/bjp.bp.107.037218","volume":"192","author":"S Lewis","year":"2008","unstructured":"Lewis S, Lieberman J (2008) CATIE and CUtLASS: can we handle the truth? Br J Psychiatry 192:161\u2013163","journal-title":"Br J Psychiatry"},{"key":"1308_CR50","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S0026-895X(25)12558-3","volume":"27","author":"JE Leysen","year":"1985","unstructured":"Leysen JE, Gommeren W, Van Gompel P, Wynants J, Janssen PFM, Laduron PM (1985) Receptor-binding properties in vitro and in vivo of ritanserin: a very potent and long acting serotonin-S2 antagonist. Mol Pharmacol 27:600\u2013611","journal-title":"Mol Pharmacol"},{"key":"1308_CR51","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/sj.npp.1300768","volume":"30","author":"Z Li","year":"2005","unstructured":"Li Z, Huang M, Ichikawa J, Dai J, Meltzer HY (2005) N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors. Neuropsychopharmacology 30:1986\u20131995","journal-title":"Neuropsychopharmacology"},{"key":"1308_CR52","first-page":"57","volume":"25","author":"JA Lieberman","year":"1989","unstructured":"Lieberman JA, Saltz BL, Johns CA, Pollack S, Kane J (1989) Clozapine effects on tardive dyskinesia. Psychopharmacol Bull 25:57\u201362","journal-title":"Psychopharmacol Bull"},{"key":"1308_CR53","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/ddr.430180106","volume":"18","author":"JF McElroy","year":"1989","unstructured":"McElroy JF, Stimmel JJ, O\u2019Donnell JM (1989) Discriminative stimulus properties of haloperidol. Drug Dev Res 18:47\u201355","journal-title":"Drug Dev Res"},{"key":"1308_CR54","first-page":"307","volume-title":"Drug discrimination: application to drug abuse research","author":"TF Meert","year":"1991","unstructured":"Meert TF (1991) Application of drug discrimination with drugs of abuse to develop new therapeutic agents. In: Glennon RA, Jarbe TUC, Frankenheim J (eds) Drug discrimination: application to drug abuse research. NIDA (Research Monograph 116), Rockville, MD, pp 307\u2013323"},{"key":"1308_CR55","first-page":"1","volume-title":"Novel antipsychotic drugs","author":"HY Meltzer","year":"1992","unstructured":"Meltzer HY (1992) The mechanism of action of clozapine in relation to its clinical advantages. In: Meltzer HY (ed) Novel antipsychotic drugs. Raven, New York, pp 1\u201313"},{"key":"1308_CR56","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/00004714-198410000-00010","volume":"4","author":"HY Meltzer","year":"1984","unstructured":"Meltzer HY, Luchins DJ (1984) Effects of clozapine in severe tardive dyskinesia: a case report. J Clin Psychopharmacol 4:316\u2013322","journal-title":"J Clin Psychopharmacol"},{"issue":"Suppl 10","key":"1308_CR57","first-page":"47","volume":"60","author":"HY Meltzer","year":"1999","unstructured":"Meltzer HY, Jayathilake K (1999) Low-dose loxapine in the treatment of schizophrenia: is it more effective and more \u201catypical\u201d than standard-dose loxapine? J Clin Psychiatry 60(Suppl 10):47\u201351","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"1308_CR58","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/oxfordjournals.schbul.a033376","volume":"25","author":"HY Meltzer","year":"1999","unstructured":"Meltzer HY, McGurk SR (1999) The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizo Bull 25(2):233\u2013255","journal-title":"Schizo Bull"},{"key":"1308_CR59","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-3565(25)20710-8","volume":"251","author":"HY Meltzer","year":"1989","unstructured":"Meltzer HY, Matsubara S, Lee JC (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251:238\u201346","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl 14","key":"1308_CR60","first-page":"20","volume":"68","author":"JM Meyer","year":"2007","unstructured":"Meyer JM (2007) Antipsychotic safety and efficacy concerns. J Clin Psychiatry 68(Suppl 14):20\u201326","journal-title":"J Clin Psychiatry"},{"key":"1308_CR61","first-page":"853","volume":"295","author":"MJ Millan","year":"2000","unstructured":"Millan MJ (2000) Improving the treatment of Schizophrenia: focus on Serotonin (5-HT)1A Receptors. J Pharmacol Exp Ther 295:853\u2013861","journal-title":"J Pharmacol Exp Ther"},{"key":"1308_CR62","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/S0022-3565(24)37732-8","volume":"286","author":"MJ Millan","year":"1998","unstructured":"Millan MJ, Schreiber R, Dekeyne A, Rivet JM, Bervoets K, Mavridis M, Sebban C, Maurel-Remy S, Newman-Tancredi A, Spedding M, Muller O, LaVielle G, Brocco M (1998) S 16924 ((R)-2-{1-[2,3-dihydro-benzo[1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl}-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. functional profile in comparison to clozapine and haloperidol. J Pharmacol Exp Ther 286:1356\u20131373","journal-title":"J Pharmacol Exp Ther"},{"key":"1308_CR63","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0022-3565(24)38153-4","volume":"289","author":"MJ Millan","year":"1999","unstructured":"Millan MJ, Schreiber R, Monneyron S, Denorme B, Melon C, Queriaux S, Dekeyne A (1999) S-16924, a novel, potential antipsychotic with marked serotonin1A agonist properties. IV. a drug discrimination comparison with clozapine. J Pharmacol Exp Ther 289:427\u2013436","journal-title":"J Pharmacol Exp Ther"},{"key":"1308_CR64","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0022-3565(24)35260-7","volume":"292","author":"MJ Millan","year":"2000","unstructured":"Millan MJ, Brocco M, Rivet JM, Audinot V, Newman-Tancredi A, Maiofiss L, Queriaux S, Despaux N, Peglion JL, Dekeyne A (2000) S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents. J Pharmacol Exp Ther 292:54\u201366","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"1308_CR65","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.pnpbp.2003.09.006","volume":"27","author":"HJ M\u00f6ller","year":"2003","unstructured":"M\u00f6ller HJ (2003) Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27(7):1101\u20131111","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1308_CR66","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0022-3565(25)10792-1","volume":"262","author":"NA Moore","year":"1992","unstructured":"Moore NA, Tye NC, Axton MS, Risius FC (1992) The behavioral pharmacology of olanzapine, a novel \u201catypical\u201d antipsychotic agent. J Pharmacol Exp Ther 262:545\u2013551","journal-title":"J Pharmacol Exp Ther"},{"key":"1308_CR67","first-page":"281","volume":"2","author":"NA Moore","year":"1993","unstructured":"Moore NA, Calligaro DO, Wong DT, Bymaster F, Tye NC (1993) The pharmacology of olanzapine and other new antipsychotic agents. Cur Opin Invest Drugs 2:281\u2013293","journal-title":"Cur Opin Invest Drugs"},{"key":"1308_CR68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1461145704005000","volume":"8","author":"A Newman-Tancredi","year":"2005","unstructured":"Newman-Tancredi A, Assie M-B, Leduc N, Ormiere A-M, Danty N, Cosi C (2005) Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int J Neuropsychopharmacology. 8:1\u201316","journal-title":"Int J Neuropsychopharmacology."},{"key":"1308_CR69","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/BF00735891","volume":"94","author":"EB Nielsen","year":"1988","unstructured":"Nielsen EB (1988) Cholinergic mediation of the discriminative stimulus properties of clozapine. Psychopharmacology 94:115\u2013118","journal-title":"Psychopharmacology"},{"key":"1308_CR70","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1007\/BF00174358","volume":"89","author":"R Ortmann","year":"1986","unstructured":"Ortmann R, Meisburger JG, Bischoff S, Hauser K, Bittiger H, Waldmeier PC (1986) The clozapine cue in rats as tools for the characterization of neuroleptics. Psychopharmacology 89:S47, (Abstract)","journal-title":"Psychopharmacology"},{"key":"1308_CR71","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/BF00401896","volume":"10","author":"DA Overton","year":"1966","unstructured":"Overton DA (1966) State dependent learning produced by depressant and atropine-like drugs. Psychopharmacology (Berlin) 10:6\u201331","journal-title":"Psychopharmacology (Berlin)"},{"key":"1308_CR72","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/BF00449130","volume":"76","author":"DA Overton","year":"1982","unstructured":"Overton DA (1982) Comparison of the degree of discriminability of various drugs using the T-maze drug discrimination paradigm. Psychopharmacology 76:385\u2013395","journal-title":"Psychopharmacology"},{"issue":"1","key":"1308_CR73","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00213-005-2147-0","volume":"180","author":"SD Philibin","year":"2005","unstructured":"Philibin SD, Prus AJ, Pehrson AL, Porter JH (2005) Serotonin receptor mechanisms mediate the discriminative stimulus properties of the atypical antipsychotic clozapine in C57BL\/6 mice. Psychopharmacology (Berl) 180(1):49\u201356","journal-title":"Psychopharmacology (Berl)"},{"key":"1308_CR74","doi-asserted-by":"crossref","unstructured":"Philibin SD, Walentiny DM, Vunck SA, Prus, Meltzer HY, Porter JH (2008) Further characterization of the discriminative stimulus properties of the atypical antipsychotic drug clozapine in C57BL\/6 mice. Psychopharmacology (this issue)","DOI":"10.1007\/s00213-008-1385-3"},{"key":"1308_CR75","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s002130050127","volume":"128","author":"JH Porter","year":"1996","unstructured":"Porter JH, Strong SE (1996) Discriminative stimulus control with olanzapine: generalization to the atypical antipsychotic clozapine. Psychopharmacology 128:216\u2013219","journal-title":"Psychopharmacology"},{"key":"1308_CR76","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/(SICI)1098-2299(199909)48:1<38::AID-DDR5>3.0.CO;2-C","volume":"48","author":"JH Porter","year":"1998","unstructured":"Porter JH, Covington HE III, Varvel SA, Vann RE, Warren TA (1998) Chlorpromazine as a discriminative stimulus in rats: generalization to typical and atypical antipsychotic. Drug Dev Res 48:38\u201344","journal-title":"Drug Dev Res"},{"key":"1308_CR77","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/(SICI)1098-2299(199902)46:2<139::AID-DDR7>3.0.CO;2-S","volume":"46","author":"JH Porter","year":"1999","unstructured":"Porter JH, Villanueva HF, Rosecrans JA (1999) The role of D1 and D2 dopamine receptors in the discriminative stimulus properties of the atypical antipsychotic clozapine in rats. Drug Dev Res 46:139\u2013147","journal-title":"Drug Dev Res"},{"key":"1308_CR78","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s002130050046","volume":"148","author":"JH Porter","year":"2000","unstructured":"Porter JH, McCallum SE, Varvel SA, Vann RE (2000a) The discriminative stimulus properties of the atypical antipsychotic olanzapine in rats. Psychopharmacology 148:224\u2013233","journal-title":"Psychopharmacology"},{"key":"1308_CR79","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s002139900366","volume":"149","author":"JH Porter","year":"2000","unstructured":"Porter JH, Varvel SA, Vann RE, Philibin SD, Wise LE (2000b) Clozapine drug discrimination with a low training dose distinguishes atypical from typical antipsychotic drugs in rats. Psychopharmacology 149:189\u2013193","journal-title":"Psychopharmacology"},{"key":"1308_CR80","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00213-004-1985-5","volume":"178","author":"JH Porter","year":"2005","unstructured":"Porter JH, Prus AJ, Vann RE, Varvel SA (2005) Discriminative stimulus properties of the atypical antipsychotic clozapine and the typical antipsychotic chlorpromazine in a three-choice drug discrimination procedure in rats. Psychopharmacology (Berl) 178:67\u201377","journal-title":"Psychopharmacology (Berl)"},{"key":"1308_CR81","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/FBP.0b013e32830cd84e","volume":"19","author":"JH Porter","year":"2008","unstructured":"Porter JH, Walentiny DM, Philibin SC, Vunck SA, Crabbe JC (2008) A comparison of the discriminative stimulus properties of the atypical antipsychotic drug clozapine in DBA\/2 and C57BL\/6 inbred mice. Behav Pharmacol 19:530\u2013542","journal-title":"Behav Pharmacol"},{"key":"1308_CR82","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.pbb.2003.10.010","volume":"77","author":"AJ Prus","year":"2004","unstructured":"Prus AJ, Baker LE, Meltzer HY (2004) Discriminative stimulus properties of 1.25 and 5.0 mg\/kg doses of clozapine in rats: examination of the role of dopamine, serotonin, and muscarinic receptor mechanisms. Pharmacol Biochem Behav 77:199\u2013208","journal-title":"Pharmacol Biochem Behav"},{"key":"1308_CR83","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/01.fbp.0000172735.73876.06","volume":"16","author":"AJ Prus","year":"2005","unstructured":"Prus AJ, Philibin SD, Pehrson AL, Porter JH (2005a) Generalization to atypical antipsychotic drugs depends on training dose in rats trained to discriminate 1.25\u00a0mg\/kg clozapine versus 5.0\u00a0mg\/kg clozapine versus vehicle in a three-choice drug discrimination task. Behav Pharmacol 16:511\u2013520","journal-title":"Behav Pharmacol"},{"key":"1308_CR84","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/ddr.10419","volume":"64","author":"AJ Prus","year":"2005","unstructured":"Prus AJ, Philibin SD, Pehrson AL, Stephens CL, Cooper RN, Wise LE, Porter JH (2005b) Generalization testing with atypical and typical antipsychotic drugs in rats trained to discriminate 5.0 mg\/kg clozapine from vehicle in a two-choice drug discrimination task. Drug Dev Res 64:55\u201365","journal-title":"Drug Dev Res"},{"key":"1308_CR85","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/01.fbp.0000197457.70774.91","volume":"17","author":"AJ Prus","year":"2006","unstructured":"Prus AJ, Philibin SD, Pehrson AL, Porter JH (2006) Discriminative stimulus properties of the atypical antipsychotic drug clozapine in rats trained to discriminate 1.25\u00a0mg\/kg clozapine vs5.0\u00a0mg\/kg clozapine vs. vehicle. Behav Pharmacol 17:185\u2013194","journal-title":"Behav Pharmacol"},{"key":"1308_CR86","doi-asserted-by":"crossref","unstructured":"Prus AJ, Pehrson AL, Philibin SD, Wood JT, Vunck SA, Porter JH (2008) The role of M1 muscarinic cholinergic receptors in the discriminative stimulus properties of N-desmethylclozapine and the atypical antipsychotic drug clozapine. Psychopharmacology (this issue)","DOI":"10.1007\/s00213-008-1262-0"},{"key":"1308_CR87","unstructured":"Reuters (2008) ACADIA pharmaceuticals announces results from ACP-104 Phase IIb Schizophrenia Trial. Press Release, June 16, 2008 http:\/\/www.reuters.com\/article\/pressRelease\/idUS100572+16-Jun-2008+BW20080616"},{"key":"1308_CR88","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/026988119701100301","volume":"11","author":"GP Reynolds","year":"1997","unstructured":"Reynolds GP (1997) What is an atypical antipsychotic? J Psychopharmacol 11:195\u2013199","journal-title":"J Psychopharmacol"},{"issue":"Suppl 10","key":"1308_CR89","first-page":"5","volume":"60","author":"E Richelson","year":"1999","unstructured":"Richelson E (1999) Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 60(Suppl 10):5\u201314","journal-title":"J Clin Psychiatry"},{"key":"1308_CR90","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/S0022-3565(25)11452-3","volume":"260","author":"BL Roth","year":"1992","unstructured":"Roth BL, Ciaranello RD, Meltzer HY (1992) Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors. J Pharmacol Exp Ther 260:1361\u20131365","journal-title":"J Pharmacol Exp Ther"},{"key":"1308_CR91","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0022-3565(25)38596-4","volume":"268","author":"BL Roth","year":"1994","unstructured":"Roth BL, Craigo MC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY, Sibley DR (1994) Binding of typical and atypical antipsychotics agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268:1403\u20131410","journal-title":"J Pharmacol Exp Ther"},{"key":"1308_CR92","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0014-2999(94)90643-2","volume":"264","author":"R Schreiber","year":"1994","unstructured":"Schreiber R, Brocco M, Millan MJ (1994) Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the \u2018atypical\u2019 antipsychotics, clozapine and risperidone. Eur J Pharmacol 264:99\u2013102","journal-title":"Eur J Pharmacol"},{"key":"1308_CR93","unstructured":"Schmidt WJ, Volz TL (1992) Clozapine-like discriminate stimulus effects of N-methyl-d-aspartate (NMDA). Journal of Psychopharmacology (Suppl.), Abstract: BAP and EBPS Joint Meeting, Cambridge"},{"key":"1308_CR94","first-page":"85","volume-title":"Advances in behavioral pharmacology (Vol. 1)","author":"CR Schuster","year":"1997","unstructured":"Schuster CR, Balster RL (1997) The discriminative stimulus properties of drugs. In: Thompson T, Dews PB (eds) Advances in behavioral pharmacology (Vol. 1). Academic, New York, pp 85\u2013138"},{"key":"1308_CR95","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF02245606","volume":"124","author":"A Schotte","year":"1996","unstructured":"Schotte A, Janssen PFM, Gommeren W, Luyten WHML, Van Gompel P, Lesag AS, De Loore K, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124:57\u201373","journal-title":"Psychopharmacology"},{"key":"1308_CR96","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","volume":"28","author":"DA Shapiro","year":"2003","unstructured":"Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28:1400\u20131411","journal-title":"Neuropsychopharmacology"},{"key":"1308_CR97","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1037\/1064-1297.10.4.376","volume":"10","author":"JA Smith","year":"2002","unstructured":"Smith JA, Goudie AJ (2002) Discriminative stimulus properties in rats of the novel antipsychotic quetiapine. Exp Clin Psychopharmacol 10:376\u2013384","journal-title":"Exp Clin Psychopharmacol"},{"issue":"Suppl","key":"1308_CR98","doi-asserted-by":"crossref","first-page":"A57","DOI":"10.1007\/s002130050739","volume":"12","author":"JA Smith","year":"1998","unstructured":"Smith JA, Taylor A, Goudie AJ, Kilpatrick IC, Needham PL (1998) Discriminative stimulus properties of the antipsychotic zotepine in clozapine cued rats. J Psychopharmacol 12(Suppl):A57","journal-title":"J Psychopharmacol"},{"key":"1308_CR99","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0022-3565(25)38366-7","volume":"266","author":"SM Sorensen","year":"1993","unstructured":"Sorensen SM, Kehne JH, Fadayel GM, Humphreys TM, Ketteler HJ, Sullivan CK, Taylor VL, Schmidt CJ (1993) Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J Pharmacol Exp Ther 266:684\u2013691","journal-title":"J Pharmacol Exp Ther"},{"key":"1308_CR100","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/BF00408342","volume":"3","author":"J Stewart","year":"1962","unstructured":"Stewart J (1962) Differential responses based on the physiological consequences of pharmacological agents. Psychopharmacologia 3:132\u2013138","journal-title":"Psychopharmacologia"},{"issue":"Suppl","key":"1308_CR101","first-page":"18","volume":"5","author":"IP Stolerman","year":"1994","unstructured":"Stolerman IP, Mariathasan EA, White J-AW (1994) Implications of mixture research for discrimination of single drugs. Behav Pharmacol 5(Suppl):18","journal-title":"Behav Pharmacol"},{"key":"1308_CR102","first-page":"214","volume-title":"Problems of drug dependence 1995.NIDA Monograph 162, U.S","author":"IP Stolerman","year":"1996","unstructured":"Stolerman IP, White J-AW, Mariathasan EA (1996) Generalizations between mixtures of drugs under \u201cAND\u201d and \u201cAND-OR\u201d discrimination procedures in rats. In: Harris LS (ed) Problems of drug dependence 1995.NIDA Monograph 162, U.S. Government Printing Office, Washington, DC, p 214"},{"key":"1308_CR103","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/S0022-3565(24)36573-5","volume":"281","author":"AH Tang","year":"1997","unstructured":"Tang AH, Franklin SR, Himes CS, Smith MW, Tenbrink RE (1997) PNU-96415E, a potential antipsychotic agent with clozapine-like pharmacological properties. J Pharmacol Exp Ther 281:440\u2013447","journal-title":"J Pharmacol Exp Ther"},{"key":"1308_CR104","first-page":"1571","volume":"25","author":"SA Varvel","year":"1999","unstructured":"Varvel SA, Vann RE, Wise LE, Porter JH (1999) Discriminative stimulus control with olanzapine: generalization to the atypical antipsychotic sertindole. Society for Neuroscience Abstracts 25:1571","journal-title":"Society for Neuroscience Abstracts"},{"key":"1308_CR105","first-page":"248","volume":"16","author":"HF Villanueva","year":"1990","unstructured":"Villanueva HF, Arezo S, Rosecrans JA, Porter JH (1990) Discriminative stimulus properties of clozapine. Society for Neuroscience Abstracts 16:248","journal-title":"Society for Neuroscience Abstracts"},{"issue":"2","key":"1308_CR106","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ddr.430260208","volume":"26","author":"HF Villanueva","year":"1992","unstructured":"Villanueva HF, Arezo S, Rosecrans JA (1992) Nicotine does not interact with the discriminative stimulus effects of clozapine in rats. Drug Dev Res 26(2):195\u2013202","journal-title":"Drug Dev Res"},{"key":"1308_CR107","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00213-004-1940-5","volume":"177","author":"DM Weiner","year":"2004","unstructured":"Weiner DM, Meltzer HY, Veinbergs I, Donohue EM, Spalding TA, Smith TT, Mohell N, Harvey SC, Lameh J, Nash N, Vanover KE, Olsson R, Jayathilake K, Lee M, Levey AI, Hacksell U, Burstein ES, Davis RE, Brann MR (2004) The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology (Berl) 177:207\u2013216","journal-title":"Psychopharmacology (Berl)"},{"key":"1308_CR108","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/0091-3057(92)90433-G","volume":"43","author":"JL Wiley","year":"1992","unstructured":"Wiley JL, Porter JH (1992) Serotonergic drugs do not substitute for clozapine in clozapine-trained rats in a two-lever drug discrimination procedure. Pharmacol Biochem Behav 43:961\u2013965","journal-title":"Pharmacol Biochem Behav"},{"key":"1308_CR109","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3758\/BF03334149","volume":"31","author":"JL Wiley","year":"1993","unstructured":"Wiley JL, Porter JH (1993) Effects of serotonergic drugs in rats trained to discriminate clozapine from haloperidol. Bull Psychonomic Society 31:94\u201396","journal-title":"Bull Psychonomic Society"},{"key":"1308_CR110","doi-asserted-by":"crossref","unstructured":"Winter JC, Rabin RA (1989) Yohimbine and serotonergic agonists: stimulus properties and receptor binding. In: Lal H, Fielding S (eds) Drugs as interoceptive stimuli. Drug Dev Res 16:327\u2013333","DOI":"10.1002\/ddr.430160226"},{"issue":"Suppl 1","key":"1308_CR111","first-page":"S70","volume":"18","author":"E Wood","year":"2007","unstructured":"Wood E, Pehrson AL, Wood JT, Prus AJ, Meltzer HY, Porter JH (2007) The discriminative stimulus properties of the atypical antipsychotic ziprasidone in rats. Poster Presented at the 12th Biennial European Behavioral Pharmacology Society meeting in Tubingen, Germany. Abstract Published in Behavioural Pharmacology 18(Suppl 1):S70","journal-title":"Abstract Published in Behavioural Pharmacology"},{"key":"1308_CR112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S146114570500516X","volume":"8","author":"ND Woodward","year":"2005","unstructured":"Woodward ND, Purdon SE, Meltzer HY, Zald DH (2005) A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Intern J Neuropsychopharmacol 8:1\u201316","journal-title":"Intern J Neuropsychopharmacol"},{"key":"1308_CR113","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1037\/1064-1297.5.3.216","volume":"5","author":"CR Young","year":"1997","unstructured":"Young CR, Longhurst JG, Bowers MB Jr, Mazure CM (1997) The expanding indications for clozapine. Exp Clin Psychopharm 5:216\u2013234","journal-title":"Exp Clin Psychopharm"},{"issue":"3","key":"1308_CR114","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0014-2999(96)00956-9","volume":"321","author":"XP Zeng","year":"1997","unstructured":"Zeng XP, Le F, Richelson E (1997) Muscarinic m4 receptor activation by some atypical antipsychotic drugs. Eur J Pharmacol 321(3):349\u201354","journal-title":"Eur J Pharmacol"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-008-1308-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-008-1308-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-008-1308-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T23:00:12Z","timestamp":1738364412000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-008-1308-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9,16]]},"references-count":114,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["1308"],"URL":"https:\/\/doi.org\/10.1007\/s00213-008-1308-3","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9,16]]}}}